224 related articles for article (PubMed ID: 28814166)
1. Late presentation of NMOSD as rapidly progressive leukoencephalopathy with atypical clinical and radiological findings.
Sechi E; Addis A; Batzu L; Mariotto S; Ferrari S; Conti M; Sechi G
Mult Scler; 2018 Apr; 24(5):685-688. PubMed ID: 28814166
[TBL] [Abstract][Full Text] [Related]
2. Extensive cerebral white matter involvement in a patient with NMO spectrum disorder.
Ayrignac X; Dalière CC; Nerrant E; Vincent T; De Seze J; Labauge P
Mult Scler; 2014 Sep; 20(10):1401-3. PubMed ID: 24852925
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorder mimicking extensive leukodystrophy.
Ciron J; Colin O; Rosier MP; Lapeyrie S; Biotti D; Brassat D; Neau JP
Mult Scler; 2018 Aug; 24(9):1256-1258. PubMed ID: 29676204
[TBL] [Abstract][Full Text] [Related]
4. A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion.
Sawada J; Orimoto R; Misu T; Katayama T; Aizawa H; Asanome A; Takahashi K; Saito T; Anei R; Kamada K; Miyokawa N; Takahashi T; Fujihara K; Hasebe N
Mult Scler; 2014 Sep; 20(10):1413-6. PubMed ID: 24986696
[TBL] [Abstract][Full Text] [Related]
5. Contiguous and symmetrical disease expansion and massive necrosis of the cerebral white matter in a patient with neuromyelitis optica.
Ishida C; Ikeda T; Komai K; Takahashi K; Noguchi-Shinohara M; Yamada M
Mult Scler; 2018 Aug; 24(9):1258-1261. PubMed ID: 29676196
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder.
Yoshii F; Moriya Y; Ohnuki T; Ryo M; Takahashi W
Mult Scler Relat Disord; 2016 May; 7():53-7. PubMed ID: 27237757
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
[TBL] [Abstract][Full Text] [Related]
10. Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients.
Carnero Contentti E; Daccach Marques V; Soto de Castillo I; Tkachuk V; Antunes Barreira A; Armas E; Chiganer E; de Aquino Cruz C; Di Pace JL; Hryb JP; Lavigne Moreira C; Lessa C; Molina O; Perassolo M; Soto A; Caride A
Mult Scler Relat Disord; 2018 Jan; 19():73-78. PubMed ID: 29156226
[TBL] [Abstract][Full Text] [Related]
11. Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab.
Shidahara K; Hayashi K; Sada KE; Hiramatsu S; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
Lupus; 2018 Jul; 27(8):1374-1377. PubMed ID: 29498304
[TBL] [Abstract][Full Text] [Related]
12. Neuromyelitis optica spectrum disorder mimicking multiple sclerosis.
van Rooij LC; Wattjes MP; de Jong BA; van Oosten BW
Mult Scler Relat Disord; 2017 Oct; 17():54-56. PubMed ID: 29055475
[TBL] [Abstract][Full Text] [Related]
13. Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies.
Bianchi A; Bartolini E; Melani F; Guerrini R; Mascalchi M
J Neurol; 2017 Jan; 264(1):179-181. PubMed ID: 27844163
[No Abstract] [Full Text] [Related]
14. Neuromyelitis Optica (Devic's Syndrome): an Appraisal.
Crout TM; Parks LP; Majithia V
Curr Rheumatol Rep; 2016 Aug; 18(8):54. PubMed ID: 27402111
[TBL] [Abstract][Full Text] [Related]
15. The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt.
Kishk NA; Abdelfattah W; Shalaby NM; Shehata HS; Hassan A; Hegazy MI; Abokrysha NT; Abdellatif D; Shawky SM; Abdo SS; Taha N; Fouad AM; Elmazny A; Ragab AH
BMC Neurol; 2021 Feb; 21(1):53. PubMed ID: 33535985
[TBL] [Abstract][Full Text] [Related]
16. Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report.
Bejerot S; Hesselmark E; Mobarrez F; Wallén H; Hietala MA; Nybom R; Wetterberg L
J Med Case Rep; 2019 Jan; 13(1):27. PubMed ID: 30696485
[TBL] [Abstract][Full Text] [Related]
17. Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica.
Berger JR; Neltner J; Smith C; Cambi F
Mult Scler Relat Disord; 2014 Nov; 3(6):728-31. PubMed ID: 25891552
[TBL] [Abstract][Full Text] [Related]
18. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
[TBL] [Abstract][Full Text] [Related]
19. Paraneoplastic neuromyelitis optica spectrum disorder: A case report and review of the literature.
Annus Á; Bencsik K; Obál I; Kincses ZT; Tiszlavicz L; Höftberger R; Vécsei L
J Clin Neurosci; 2018 Feb; 48():7-10. PubMed ID: 29133107
[TBL] [Abstract][Full Text] [Related]
20. Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder.
Lee MY; Yong KP; Hyun JW; Kim SH; Lee SH; Kim HJ
Neurology; 2020 Dec; 95(23):e3124-e3128. PubMed ID: 32928976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
